Early treatment may leads to higher proportion of infants receiving any pharmacotherapy for a… compared with expectant management (low certainty).
It is very uncertain whether very early treatment changes proportion of infants receiving any pharmacotherapy for a… compared with expectant management (very low certainty).
Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).
Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).
Early probably leads to lower time to death from prostate cancer (here: prostate cancer mortality… compared with deferred AST (moderate certainty).
Early may leads to lower skeletal events compared with deferred AST (low certainty).
Early may leads to higher fatigue compared with deferred AST (low certainty).
Early may leads to higher heart failure compared with deferred AST (low certainty).
Subgroup analyses: early showed no clear difference in death by AKI aetiology: non‐surgical causes compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
Subgroup analyses: early showed no clear difference in death by AKI aetiology: surgical causes compared with standard initiation of kidney replacement therapy (KRT) (low certainty).
Subgroup analyses: early showed no clear difference in kidney recovery functionby KRT: continuous KRT compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
Subgroup analyses: early showed no clear difference in kidney recovery functionby KRT: continuous and intermittent KRT compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
Early ART probably leads to lower death compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (moderate certainty).
Early ART showed no clear difference in tuberculosis compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (moderate certainty).
Early ART showed no clear difference in disease progression measured by opportunistic disease Opportunistic… compared with standard or deferred ART (CD4 <= 200 or CD4 <= 250 cells/µl) (low certainty).
INTERMITTENT (EARLY‐BASED) showed no clear difference in adverse effects: tardive dyskinesia: long term (+26 weeks) as… compared with MAINTENANCE THERAPY (low certainty).